---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-123543"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T08:57:57.487796+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA approves Corcept's Lifyorli (relacorilant) for platinum-resistant ovarian cancer

## Summary
- Lifyorli (relacorilant) plus nab-paclitaxel approved for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.
- Approval based on ROSELLA trial: 35% reduction in risk of death (HR 0.65, median OS 16.0 vs 11.9 months).
- Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA).
- Most common adverse reactions: decreased hemoglobin, neutrophils, fatigue, nausea, diarrhea, rash, decreased appetite.

## SEC filing metadata
- accession: 0001193125-26-123543
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000119312526123543/0001193125-26-123543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000119312526123543/d123475d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-123543
- JSON: https://secwatch.observer/filing/0001193125-26-123543.json
- Plain text: https://secwatch.observer/filing/0001193125-26-123543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.